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Abstract: Structural variety, tunable porosity and opportuni-
ties for functionalization make metal-organic frameworks
(MOFs) promising materials for applications in medicine as
drug delivery systems. In this minireview, an overview of
chemical stability of MOF nanocarriers at simulated body
conditions is presented. Parameters such as a choice of
buffer, pH value, nanoparticle size or surface modification are
discussed, as well as analytical methods and approaches
suitable to determine the material stability. Last but not least,
examples of tuning and improving the chemical stability of
MOF nanoparticles for solution-based drug delivery (oral and
intravenous) are presented and examples of MOFs as pH-
responsive drug nanocarriers are given.
1. Introduction
Conventional drugs based on small molecules are often
distributed at high concentrations in order to reach target
tissues at a therapeutic concentration. This can lead to a non-
selective biodistribution within the body, which might result in
a tissue damage. As an alternative to the traditional approach,
using drug delivery systems have been proposed.[1] Nano-
particles have been suggested as drug delivery platforms to
provide controlled drug delivery leading to an increase of
efficiency and decrease of side effects. Various materials have
been suggested as nanocarriers,[2–4] including metal-organic
frameworks (MOFs),[5–10] which typically possess a large drug
loading capacity (due to the high material porosity), good
biocompatibility and opportunities for functionalization.
MOFs are porous coordination polymers constructed from
organic ligands and metal-containing nodes.[11] Due to their
structural and functional tunability,[12,13] they have been consid-
ered as promising materials for various applications including
gas storage and separation,[14,15] catalysis,[16,17] sensing,[18,19]
electrical and proton conduction,[20,21] but also as nanocarriers in
drug delivery.[5–10] For many of the applications, a high chemical
and thermal stability is required and is often a crucial aspect
when considering the commercialization of the materials.
However, when considering MOFs as drug nanocarriers, a
certain material instability can lead to great benefits. For
instance, to prevent a nanoparticle accumulation within the
body, it would be convenient if the nanocarrier decomposes,
when the drug is delivered to the target. The optimal material
stability for drug delivery applications strongly depends on the
route of administration (oral, intravenous, transdermal, pulmo-
nary, etc.). In this minireview, a chemical stability of MOFs at
simulated body conditions for applications in solution-based
drug delivery (oral and intravenous) is discussed. Information
on other sorts of MOF stability, such as thermal stability and
stability in water, was reported in comprehensive reviews
previously.[22–24]
2. The origin of the chemical stability of MOFs
Chemical stability of MOFs refers to their ability to maintain
their long-ranged ordered structure in a certain chemical
environment. The strength of coordinate bonds is believed to
be responsible for the thermodynamic stability of MOFs.[25]
Thus, the stronger the coordinate bonds are, the more stable
framework is expected to be formed. The bond strength can be
predicted by applying the Pearson’s hard and soft acids and
bases (HSAB) principle.[26] According to the HSAB principle,
stable MOFs can be formed either by assembly of hard bases
(such as carboxylate ligands) with high-valent metal ions [such
as Ti(IV), Zr(IV), Al(III), Fe(III) and Cr(III)], or by assembly of soft
bases (such as imidazolate, pyrazolate, triazolate and tetrazolate
ligands) with soft divalent metal ions [such as Zn(II), Cu(II),
Mn(II), etc.]. The metal-ligand bond strengths with a given
ligand are positively correlated to charges of the metal cations
and negatively correlated to the ionic radius.
When considering the material stability, the operating
environment has to be taken into an account too. For instance,
a pH value has to be considered. A great effort has been made
to explain MOF stability in acids and bases.[27,28] In an acidic
environment, the MOF degradation is mainly caused by
competing proton and metal ions to coordinate with the
organic ligand. In a basic environment, the major driving force
of MOF decomposition is the replacement of organic ligands by
hydroxide ions. Therefore, MOFs based on high-valent metal
ions and carboxylate ligands are expected to be rather stable in
acids, while less resistant to bases. On the other hand, MOFs
based on soft divalent metal ions and azolate ligands are
expected to be more stable in basic solution and rather
unstable in acids. Additionally, the presence of additional
cations and ions in the operating environment also influences
the stability. For example, phosphate ions in a phosphate
buffered saline (PBS) can be seen as ligands, which can replace
the organic ligands in MOFs. They can be classified as a hard
Lewis base; thus, they are expected to reduce the stability
especially of carboxylate-based MOFs constructed from high-
valent metal ions. The influence of the buffer choice (with
regard to its composition) is discussed in detail in the
corresponding paragraph of this minireview.[a] Dr. H. Bunzen
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3. Analytical methods to determine the
chemical stability of MOFs
In a typical stability test, a certain amount of a MOF is dispersed
in a certain volume of a selected solution. After a certain period
of time, both the liquid and solid phases are analysed. Chemical
stability of a MOF is understood as the ability to maintain the
long-ranged ordered structure, when exposed to a certain
environment.[25] Therefore, after the material exposure, changes
to the material structure has to be assessed. There is a variety of
transformations, which may occur and they need to be
evaluated by a suitable combination of analytical methods.
Generally, there are two main ways of a material degradation to
be considered: (i) decomposition to the original building blocks
(which can further react with compounds present in the
operating environment) and (ii) amorphization.
3.1. Analysis of the solid phase
Powder X-ray diffraction: Recording powder X-ray diffraction
(PXRD) patterns is a quick and simple method to study
structural changes in a MOF. PXRD patterns of a sample before
and after the exposure are measured and compared. The
patterns can be identical, reflect slight changes, or show a
greater variation. To compare two PXRD patterns, the measure-
ments should be standardized. Falcaro et al. proposed to add a
known quantity of a crystalline internal standard, such as
commercial TiO2 (anatase).
[29] This approach allows to exclude
the possibility that changes in intensity of the diffraction peaks
resulted from fluctuations in the mass of the material from
sample to sample. The diffraction patterns are recorded and
baseline corrected. Then, the peak corresponding to the (101)
anatase (2θ=25.3°) is fitted with a Gaussian curve, and the
intensity normalized (Figure 1a).
It should be noted that a PXRD measurement is essentially
an incomplete experiment. It may give an impression of stability
arising from the retention of the peaks in a PXRD pattern.
However, this can be misleading, because even if two PXRD
patterns are apparently unchanged, it does not ultimately
confirm the stability. For example, an amorphous phase can be
formed, while the remaining sample is unchanged, or a part of
the sample can dissolve, while the residual solid remains
crystalline. Therefore, a detailed data analysis is necessary to
detect a peak broadening, thicker baseline, etc. Other subtle
changes, which is not largely captured by the PXRD measure-
ment, are surface defects possibly caused by the treatment.
Given all these possibilities, PXRD as a means of determining
chemical stability should only be used in a combination with
further characterization techniques, including studies of a
retention of mass.
Infrared spectroscopy: Infrared (IR) spectroscopy is a
suitable technique to determine, if there is a chemical change
to the framework (e.g. protonation of the ligand, additional
coordination of the solution components to the framework,
etc.). The information is then combined with results from other
methods to assess, if the structure has changed. Falcaro et al.
used IR spectroscopy to show changes in ZIF-8 after exposing it
to PBS.[29] They reported on a progressive decrease in the peak
intensity of vibration modes related to 2-methylimidazolate
ligand and of the band attributed to the Zn  N stretching mode.
The data suggested that the degradation process of ZIF-8
involved the release of the ligand with a change in the
coordination environment of the Zn(II) ions. Moreover, new
vibrational mode were detected at 1160–900 cm  1 and 660–
530 cm  1 with increasing intensity over time. These bands were
assigned to the antisymmetric stretching and bending mode of
PO4
3  groups, respectively, indicating that the phosphate ions
from the buffer solution reacted with released zinc ions to form
zinc phosphates as a degradation product.
Electron microscopy: To determine changes in a particle
size or morphology, electron microscopy is often employed.
The methods include atomic force microscopy (AFM), scanning
electron microscopy (SEM) and transmission electron micro-
scopy (TEM). For instance, AFM images of ZIF-8 particles were
taken to follow etching of the external surface of the particles
(Figure 1b).[29] The micrographs showed a faster degradation of
nanoparticles in comparison to microsized particles as a result
of the larger surface area of the nanoparticles being exposed to
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Figure 1. a) PXRD patterns illustrating the structural evolution of ZIF-8
particles before and after the incubation process in PBS, and b) evaluation
of the degradation process followed by in situ AFM experiments. Adapted
from Ref. [29] with permission from the Royal Society of Chemistry.
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PBS. Moreover, electron microscopes often provide the possi-
bility to performed energy-dispersive X-ray spectroscopy (EDX),
which can be used for an elemental analysis of the solid.
Similarly, Gassensmith et al. studied the changes in morphology
of 1 μm large ZIF-8 crystals exposed to various buffers and cell
media by time resolved SEM microscopy combined with EDX.[30]
3.2. Analysis of the liquid phase
Mass balance: Checking if a MOF is ‘dissolving’ should be one
of the first properties to study, when determining the material
chemical stability. This can involve weighing the sample pre-
and post- stability tests or monitoring the parent solution. Since
it is rather difficult to isolate the material quantitatively
(especially if well-dispersible nanoparticles of a size of tens of
nanometres are used) and make sure that there are no
components or solvent molecules of the operating environment
trapped in the pores, an indirect method based on monitoring
the possibly released MOF components into the solution is
usually preferred. If the products of the material degradation
are soluble in the tested environment, their amount can be
determined and used to quantify the degradation process.
However, if that it is not the case and the components are
insoluble (as some organic ligands are in aqueous solutions) or
react with the buffer medium to form insoluble compounds
(i. e. released metal ions to form inorganic salts with the anions
present in the operating environment), other methods of a
stability determination have to be used. Keeping this in mind,
the solubility of the MOF components in the selected operating
environment should be tested before the actual MOF stability
tests are carried out. The amount of an organic ligand can be
determined by various methods (depending on the ligand
properties) including high performance liquid chromatography
(HPLC), ultraviolet-visible light (UV-VIS) spectroscopy, gas
chromatography coupled with mass spectrometry (GC-MS), or
nuclear magnetic resonance (NMR) spectroscopy. The amount
of the released metal ions is usually determined by inductively
coupled plasma mass spectrometry (ICP-MS), or inductively
coupled plasma optical emission spectrometry (ICP-OES).
Forgan et al. determined the amount of the ligand (tereph-
thalic acid) released from UiO-66 in PBS by UV-Vis spectroscopy.
At different times, 1 mL of liquid was taken and replaced with
1 mL of fresh PBS. The absorbance of the removed solution was
measured and by employing a calibration curve, the amount of
the released ligand was determined.[31] In another work, Demel
et al. used HPLC (for the ligand determination) and ICP-MS (for
the metal determination) to monitor degradation of the UiO-66
in various buffers and in water.[32] Horcajada et al. also used
HPLC as an analytical method to determine the amount of
ligand (trimesic acid) released from MIL-100(Fe) into various
media.[33,34] Falcaro et al. determined the amount of the ligand
(2-methylimidazole) released from ZIF-8 into PBS by carrying
out GC-MS measurements.[29] Gassensmith et al. followed the
Zn-release from ZIF-8 by ICP-MS.[30]
It should be noted that one method cannot do it all and
that a suitable combination of analytical methods has to be
employed to determine the material stability. As a minimal
requirement to assess the material stability, PXRD, IR spectro-
scopy and one microscopy technique should be used to analyse
the solid, and at least one method to quantify the amount of
the ligand and metal ions released into the solution. To
describe and understand the degradation process in detail,
additional measurements are usually needed, such as small-
angle X-ray scattering, pair distribution function analysis,
computation modelling, etc.
4. Experimental set-up and influence of
experimental parameters
Just as there are different methods available for assessing the
materials stability, there are also different parameters to be
consider, when carrying out the stability tests. Besides the
material itself (i. e. internal factors such as the type of the metal-
ligand coordinate bond, coordination geometry, etc.), the
experimental set-up (i. e. external factors including the choice of
the operating environment, temperature, concentration, time,
etc.) effects the outcome of the stability tests too.
In a typical stability test, a defined amount of the MOF is
dispersed in a defined volume of a selected solution. After
dispersing MOF nanoparticles in the solution (either in a
closable container or dialysis bag), the suspension is kept at a
defined temperature – usually 37 °C to simulate the body
temperature. Sometimes the samples are stirred or shaken (to
mimic the bloodstream), sometimes not. After a certain period
of time, the liquid and solid phases are analysed (by a
combination of methods described in the previous chapter).
When reporting on results of chemical stability, the exposure
conditions (i. e. type of the operating environment and its
strength, temperature, concentration, time and the experimen-
tal set-up in general) need to be specified, because they effect
the results as demonstrated on the examples given in the
following paragraphs.
4.1. Influence of time
The material chemical stability as a function of time is one of
the most important factors to study. The optimal required
stability depends on the application and route of administration
intended. For some applications, a long-term stability over
several days is desired, for other applications, stability over few
hours might be sufficient. As a benchmark, 24 hours should be
adopted as the initial treatment time, with subsequent treat-
ment times depending on the initial result.
4.2. Operating environment
The operating environment (external factor) and the MOF
structure (internal factor; described in the second chapter) are
the two major aspects that affect the chemical stability of the
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material. Depending on the desired application of the nano-
carrier, different operating environments might be better
suited. In the simplest experiment, water is used as a solution.
However, water does not simulate the body conditions well.
Therefore, solutions containing various ions and molecules
(including proteins) at concentrations found in the body are
usually preferred.[35] Additionally, to maintain the pH value,
these solutions are most of the time buffered.[36] An overview
on common solutions used to simulate body conditions is given
in Table 1.
PBS is one of the most commonly used buffer solutions for
determining MOF stability, because its ion concentration and
osmolarity mimic well the conditions found in the body. It has
been shown that the phosphate ions presented in the solution
attacked metal ions or clusters of MOFs resulting in a ligand
substitution followed by MOF degradation. Fairen-Jimenez et al.
studied the degradation of Zr(IV)-carboxylate MOFs in PBS and
in water.[37] As expected, phosphate groups (PO4
3  ) present in
the PBS buffer attacked the metal clusters of the MOFs,
substituting the carboxylic ligands (as observed by FTIR
measurements), and finally disrupting the crystalline MOF
structure (as observed by PXRD measurements). In another
study, Falcaro et al. reported on the stability of ZIF-8 particles
exposed to PBS. They showed that the phosphate ions reacted
with released zinc ions to form zinc phosphate.[29]
Demel et al. reported on a comprehensive study comparing
the stability of UiO-66 in different buffers, namely 2-amino-2-
(hydroxymethyl)-1,3-propanediol (TRIS), 4-(2-hydroxyethyl)
piperazine-1-ethane sulfonic acid (HEPES), N-ethylmorpholine
(NEM) and phosphate buffer (PB).[32] The stability of the material
was assessed by monitoring the release of the terephthalate
ligand (determined by HPLC, Figure 2) and zirconium ions
(determined by ICP-MS). The authors showed that the chemical
nature of the buffer media played a decisive role in the MOF
stability. Buffers containing large amount of saline forms were
found to be more destructive (Figure 2). The HEPES and TRIS
buffers were found to be relatively benign, whereas NEM and
PB showed a rapid degradation of the UiO-66 framework.
Similarly, Gassensmith et al. reported on the stability of ZIF-
8 exposed to various media, including common buffers (PB,
HEPES, TRIS, bicarobonate buffer), cell media and serum.[30] They
studied not only the changes in the MOF structure, morphology
and crystallinity, but also the influence of the operating
environment on the release of cargo represented by green
fluorescent protein biomimetically mineralized within ZIF-8. It
was reported that buffers containing phosphate and bicarbon-
ate influenced the morphology and composition of ZIF-8, but
they did not cause cargo to leak out, whereas, serum dissolved
ZIF-8 resulting in a premature cargo release.
Horcajada et al. studied the degradation of MIL-100(Fe) in
water and in PBS with and without bovine serum albumin
(BSA).[33] The release of the organic ligand was followed by
HPLC (Figure 3a). The results suggested that the MOF nano-
particles were stable in water with a very low amount of the
ligand released after 24 h (2.5�0.4 wt%), but much less stable
in PBS exhibiting a faster initial degradation of 22.3�2.1 wt%
during the first 6 h and a smoother degradation profile unto
29.9�2.1 wt% after 24 h. The addition of BSA to the PBS
Table 1. Overview of buffer solutions[36] and simulated fluids[35] often used













PB Phosphate buffer Composition: Na2HPO4, KH2PO4
Buffer range: 6.3–7.3
pKa=6.78 (35 °C)




pH 7.4 (pH can be adjusted using
HCl or NaOH)
SBF Simulated body fluid Composition: NaCl, NaHCO3, KCl,
K2HPO4, MgCl2, HCl, CaCl2, Na2SO4,
tris(hydroxymethyl)aminomethane
pH 7.4; used to simulate human
blood plasma.
SIF Simulated intestinal fluid Composition: sodium taurocholate,
lecitin, maleic acid, NaOH, NaCl
pH 6.5; used to simulate prepran-
dial conditions in the upper small
intestine.
SGF Simulated gastric fluid Composition: sodium taurocholate,
lecithin, pepsin, NaCl
pH 1.6; used to simulate condi-
tions in the stomach (fasted-state).
Figure 2. Release of the ligand (terephthalic acid) from UiO-66 in 0.01 M TRIS, HEPES and PB buffers at pH 7.5 and in their saline forms containing 0.15 M NaCl.
Reproduced from Ref. [32] with permission from the Royal Society of Chemistry.
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medium (5.4% w/v) resulted in a reduction of the kinetics of
degradation (15.1�2.7 wt% after 24 h). This effect was attrib-
uted to the presence of the BSA protein corona around the
nanoparticles, that could hamper the diffusion of the phos-
phates inside the MOF structure and hence the progressive
replacement of the ligands by phosphates. To mimic the
conditions of an oral distribution, the stability of MIL-100(Fe)
was further studied in simulated intestinal fluid (SIF) and HCl
(Figure 3b). Interestingly, the 24 h degradation of the particles
in gastric (21.0�6.6 wt% in HCl, pH 1.2) and intestinal (18.2�
0.3 wt% in SIF) conditions was similar to that in PBS (29.9�
2.1 wt%). Similarly as in PBS, the presence of phosphates in
intestinal conditions induced a progressive replacement of the
carboxylic ligands in the structure and thus the dissembling of
the nanoparticles. At pH 1.2, the ligands were protonated,
which led to the structure degradation. For a better under-
standing of the interaction of MIL-100(Fe) with enzymes
secreted by the pancreas in the intestinal tract, the authors
carried out additional stability studies in lis-SIF supplemented
with pancreatin and mucin. Mucin was found to coat the
nanoparticles to form a protective layer, which prevented the
nanoparticles from a contact with the surrounding medium,
which resulted in a significantly lower ligand release (1.6�
0.1 wt%).
It should be noted that not only the type but also the
concentration (strength) of the operating environment influ-
ence the material stability. For instance, Demel et al. demon-
strated that the stability of UiO-66 in TRIS, HEPES, PB and NEM
significantly varied base on the buffer concentration varying
from 0.01 to 1.0 mol/L.[32] Therefore, it is important that the
buffer concentration is always mentioned when reporting on
the stability results.
4.3. Temperature
After dispersing MOF nanoparticles in the selected solution, the
suspension is kept at a defined temperature – usually 37 °C to
simulate the body temperature. However, there are also some
studies reported, which were carried out at 25 °C or at a not
precisely defined “room temperature”. Since it has been shown
by Demel et al. on an example of UiO-66 (studied at 25 and
37 °C in PB, TRIS and HEPES buffers),[32] that the chemical
stability depends on the temperature used in the experiments,
to mimic the body conditions, temperature of 37 °C should be
preferred in studies dealing with chemical stability of MOFs for
applications in nanomedicine. Moreover, it might be useful to
also study the material chemical stability at higher temperature
(e.g. around 42 °C) to unlock the potential use of the material in
temperature triggered drug delivery and hyperthermia
therapy.[38] Qian et al. reported on a temperature triggered drug
release of methotrexate from a Zn-TBDA MOF (TBDA, 4’-(1H-
tetrazol-5-yl)-[1,1’-biphenyl]-3,5-dicarboxylic acid).[39] They
showed that at 37 °C after 48 h at pH 7.4, 43% of methotrexate
was released, whereas at 42 °C, it was almost 80%. However, it
was not shown, if it was caused by a different material stability
at these two temperatures.
4.4. Concentration
In a typical stability test a defined amount of the MOF is
dispersed at a defined volume of a selected solution. The used
concentration quite varies, most of the time being between
0.1 mg of a MOF in 1 mL of the solution to 1 mg/mL. Systematic
studies, which would report on the influence of the different
experimental concentrations on the material stability (and if
there is any) are unfortunately missing. Optimally, the same
concentration, at which the nanocarrier is intended to be used
in in vivo experiments, should be also used in the stability
studies.
4.5. Particle size
Particle size is an important property of a nanocarrier. Depend-
ing on the intended application and the route of administration,
different MOF particle sizes are preferred.[40] For instance,
nanoparticles smaller than 200 nm are believed to be capable
of passive targeting in cancer therapy due to the enhanced
permeability and retention effect.[41] It should be noted that the
Figure 3. Degradation kinetics of MIL-100(Fe) nanoparticles at 37 °C as a
function of time in different physiological media: (a) water, 0.3 mM NaOH
pH 7.4, PBS pH 7.4, and PBS+BSA, and (b) HCl pH 1.2, lis-SIF, lis-SIF
supplemented with pancreatin, and lis-SIF supplemented with mucine.
Degradation is represented as the wt % of the linker released from the MOF
into the medium determined by HPLC. Adapted with permission from
Ref. [33]. Copyright (2014) American Chemical Society.
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particle size does not decide only on the fate of nanoparticles
in the body, but also affects the material chemical stability. For
instance, Falcaro et al. presented a study of ZIF-8 particles of
two different particle sizes (2 μm and 250 nm) exposed to
PBS.[29] They demonstrated that the kinetics of the decomposi-
tion depended on the particles size and was faster for smaller
particles. Therefore, prior the experiments, the material particle
size should be determined and reported in every study.
4.6. pH value
A pH value is one of the most discussed parameters in the
stability studies of nanocarriers for cancer treatment. Due to the
metabolism of cancer cells, the environment of cancer tissues is
slightly more acidic in comparison to the blood and normal
tissues (pH 7.4).[42] Therefore, if a nanocarrier, which is stable at
pH 7.4, but decomposes at slightly acidic conditions, is used,
not only that the nanoparticle accumulation within the body is
prevented, but also a site-specific drug release can be achieved.
This approach has been also suggested for drug delivery with
MOF nanoparticles in cancer therapy.[8,9] Therefore, if an
application of MOFs in cancer treatment is intended, then the
material stability should be studied not only at pH 7.4, but also
at slightly acidic conditions. In most of such studies, a pH value
between 5.5–6.5 is used. On the other hand, if an oral
administration is intended, such MOFs should be stable at
acidic conditions (to protect the drug from gastric acid), but
decompose in the intestine to release the drug, which is then
absorbed. There are only several studies demonstrating the
chemical stability of “empty” MOFs at different pH values. These
examples include ZIF-8,[29] UiO-66,[31,32] or MIL-100(Fe).[33] Usually,
most of such studies are carried out with MOF nanoparticles
loaded with drug molecules and it is often concluded that the
different drug release at different pH values is a result of the
different material stability at the pH values. However, without
studying also the ‘empty’ MOFs, such conclusions can be
misleading, because also other effects (e.g. different interaction
between the framework and drug molecules at different pH
values as a result of framework or drug protonation, etc.) can
be involved and effect the drug release kinetics. In the following
overview, examples, where the drug release was triggered by
the different material stability at the different pH values, are
primary given.
pH-responsive release from Zn-MOFs: Several Zn-MOFs
have been reported as pH-responsive nanocarriers for drug
delivery.[6,8] A typical example being ZIF-8, which have been
reviewed recently.[43,44] For instance, ZIF-8 has been reported as
a pH-responsive carrier of anticancer drugs such as
doxorubicin,[45,46] camptothecin,[47] 5-fluorouracil,[48] or arsenic
trioxide.[49,50] In all these examples, the drug release was faster
at acidic pH than at pH 7.4.
Qian et al. reported on a MOF Zn-TBDA (TBDA, 4’-(1H-
tetrazol-5-yl)-[1,1’-biphenyl]-3,5-dicarboxylic acid), which they
loaded with methotrexate. They showed that in PBS at 37 °C,
only 43% of the drug was released at pH 7.4 over 48 h, whereas
at pH 6.5 it was 61% due to the influence of the acidic
environment on the MOF structure.[39] In another work, MOFs
Zn-MOF-74[51] and MFU-4 l[52] were used as pH-responsive nano-
carriers of arsenic trioxide. In both cases, it was shown that the
drug release was faster at pH 6.0 than at pH 7.4 as a result of
the accelerated material decomposition at the more acidic
environment.
pH-responsive release from Fe-MOFs: MIL-100(Fe) is a
typical example of an iron MOF often proposed for drug
delivery due to its biocompatibility.[33] Based on the HSAB
concept,[26] Fe(III)-carboxylate MOFs are expected be more
stable in acids than in bases (see the second chapter for an
explanation). However, Fan et al. reported on a core-shell
structure polypyrrole@MIL-100(Fe) loaded with doxorubicin,
which exhibited a pH-responsive drug release in PBS at 37 °C.[53]
Around 42.7% of doxorubicin was released after 24 h in the
neutral PBS (pH 7.4), whereas 82.7% was released at pH 5.0. In
acidic conditions the NH2-group of doxorubicin got protonated,
which weakened the electrostatic interactions between the
drug and MOF, and thus facilitated the drug release.
Huang et al. reported on an Fe-MOF composed of Fe(II) ions
and 1,1’-(1,4-butanediyl)bis(imidazole) loaded with
doxorubicin.[54] Due to the sensitivity of the Fe(II)-imidazolate
coordinate bonds to acidic environment, the drug was release
faster at pH 5.5 than at pH 7.4. The rapid decomposition of the
nanocarrier (and thus the drug release) at low pH could be
slowed down by coating the MOF surface with a layer of silica.
pH-responsive release from Zr-MOFs: Based on the HSAB
concept,[26] Zr(IV)-carboxylate MOFs are expected to be rather
stable in acids, while less resistant to bases (see the second
chapter for an explanation). However, there are several reports
in literature showing an accelerated drug release from Zr(IV)-
carboxylate MOFs in an acidic environment. However, in these
examples the triggered drug release is not due to increase
framework instability at lower pH values, but rather due to the
drug-framework interactions being affected by the environ-
ment. Shi et al. reported on a pH-responsive behaviour of UiO-
66 for delivery of alendronate.[55] The drug was anchored to the
Zr  O clusters. The release of the drug, tested in PBS buffer at
37 °C, was faster at pH 5.5 (59%) than at pH 7.4 (43%). This was
possible because alendronate was protonated in the acidic
environment, which weakened the interaction between the
drug and the Zr  O clusters in UiO-66. However, because UiO-66
has a lower degradation rate under acidic conditions than
under neutral and basic conditions,[31,32] after 108 h, the amount
of the drug released at pH 7.4 was higher than that released at
pH 5.5. Similarly, Qian et al. reported on a cationic MOF (ZJU-
101) built from zirconium and 2,2’-bipyridine-5,5’-dicarboxylate
for the delivery of the anionic drug diclofenac sodium.[56] The
release of the drug was more rapid in PBS at pH 5.4 than at
pH 7.4, because ion exchange between the drug and anions
occurred more frequently in acidic environments, which dis-
charged the coulombic interaction between the positively
charged ZJU-101 and negatively charged drug.
On the other hand, due to the higher stability of Zr(IV)-
carboxylate MOFs in acidic conditions, Zr-MOFs have been
tested as drug nanocarriers for oral delivery. Qian et al.
suggested that a porphyrin-based Zr-MOF (PCN-221) could pass
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the stomach and gastrointestinal tract and safely deliver the
cargo to body parts with higher pH levels.[57] However, the
experiments were demonstrated only in-vitro on PC12 rat cells.
They loaded PCN-221 with methotrexate and studied the drug
release in PBS at 37 °C at pH 7.4 (pH close to the intestinal pH)
and at pH 2.0 (pH close to the pH of the stomach). After 72 h,
only around 40% of the loaded drug was released at pH 2.0, but
100% at pH 7.4. In another work, Farha et al. reported on an
immobilization of insulin in an acid stable MOF, NU-1000.[58]
Due to the protective effect from NU-1000, insulin was stable
even upon exposure to stomach acid (pH 1.5–3.5) and pepsin.
Moreover, 40 wt% of insulin could be released from the host
framework under simulated physiological conditions (pH 7.0)
(Figure 4).
5. Tuning MOF stability
In general, two main approaches have been adopted to
improve the chemical stability of MOFs: (i) de novo synthesis of
MOFs, and (ii) improving stability of existing MOFs.
5.1. De novo synthesis
The de novo synthesis widely relies on the HSAB principle.[26]
Carboxylate ligands and high-valent metals are expected to
form chemically stable MOFs. Additionally, also phosphonate
and phenolate-based ligands are expected to form stable
frameworks with high-valent metals, although they have not
been widely used in medicinal applications yet. Apart from
high-valent metal ions, soft low-valent metal ions can also
construct stable frameworks, if they are combined with soft
ligands such as N-containing ligands (imidazolates, pyrazolates,
triazolates, and tetrazolates). When designing new MOFs for
medicinal applications, due to the potential material toxicity,
the components selection is rather limited. For this reason,
MOFs comprising iron and zinc ions, and no or low toxic ligands
are mainly used. Besides the strength of the coordinate bond,
which determines the thermodynamic stability, also kinetic
factors such as framework rigidity has to be considered. Dense
and rigid structures are typically more stable. For instance,
when the stability of isoreticular MOFs UiO-66 and UiO-67 was
investigated, decreased stability with an increase in ligand
length was observed.[59]
5.2. Tuning stability of existing MOFs
Coating the nanoparticle surface by polymers has been
proposed as an efficient method to improve the chemical
stability of MOFs.[60,61] There are many examples of drug
nanocarriers, which have been coated by polyethylene glycol
(PEG) to improve their stability (both chemical and colloidal).[62]
For example, Forgan et al. coated UiO-66 nanoparticles with
PEG550 and PEG2000.[31] They showed that the polymer coating
enhanced the stability of the nanoparticles in PBS (Figure 5).
Similarly, Horcajada et al. reported on stability of MIL-100(Fe).
They showed that the degradation could be slowed down by
coating the nanoparticles with chitosan.[34]
6. Summary and Outlook
Chemical stability of MOF nanoparticles depends on many
different parameters including the experimental set-up. There-
fore, when discussing and presenting the results, the exposure
conditions (i. e. type of the operating environment and its
strength, temperature, concentration, time, particle size, etc.)
have to be specified. As analytical methods, PXRD, IR spectro-
scopy and one microscopy technique should be used to analyse
the solid, and at least one method of quantifying the amount of
the ligand and metal ions released into the solution.
Although, we have already learnt a lot about MOF stability
with regard to their potential applications in nanomedicine as
Figure 4. Schematic representation of exposure of free insulin and insulin@-
NU-1000 to stomach acid. Adapted with permission from Ref. [58]. Copyright
(2018) American Chemical Society.
Figure 5. Degradation profiles of UiO-66, UiO-66-PEG550, and UiO-66-
PEG2000 in PBS (pH 7.4) determined by UV-Vis spectroscopy. Error bars
denote standard deviations from triplicate experiments. Adapted from
Ref. [31], Copyright (2017), with permission from Elsevier.
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drug delivery systems. There are still some remaining issues to
be considered and addressed:
1) More systematic studies, which use a combination of
analytical methods, need to be carried out. For instance, it is
not sufficient to carry out drug release studies and conclude
that the different release at different pH values is a result of
different material degradation at these pH values, without
studying the material stability without the drug, because
there are also other factors, which can contribute to the pH-
triggered drug release than just the material stability.
2) Stability studies should be carried out in simulated con-
ditions, which are as close as possible to in vivo conditions.
This includes a suitable selection of the operating environ-
ment, concentration, temperature, etc. as well as suitable
particle surface modification.
3) Although, there are reports on stability studies of MOF
nanoparticles carried out at simulated body conditions,
studies linking and translating the results to studies carried
out in vivo are scare. However, such studies are needed and
are crucial for an effective translation of MOF nanoparticles
from bench to bed.
4) There is also a lack of clarity around the meaning of MOF
stability. Does stability refer to the structure retention or
function retention, or both? In this review, stability was
discussed as an ability to retain the structure. However,
there is no clear view concerning the remaining function
upon the exposure. It has been shown that MOFs, which lost
their crystallinity, can be efficient in drug delivery and
sometimes even exhibit better results than the related
crystalline equivalents.[37,63]
5) Last but not least, it should be noted that in the minireview,
examples of solution-based drug delivery (oral or intra-
venous) were primarily discussed and that for other routes
of administration (transdermal, pulmonary, etc.), different
experimental set-ups and requirements of the material
stability are expected. Additionally, the stability in formula-
tion, processing, pelletisation, etc. should be also consid-
ered.
However, despite the mentioned issues, there is no doubt
that MOFs still remain one of the most promising materials for
drug delivery.
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